Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2007; 98(01): 126-128DOI: 10.1160/TH07-05-0363 Anniversary Issue Contribution Schattauer GmbH Thrombosis and cancer: A personal view Maria Benedetta Donati 1 Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy › Author Affiliations Recommend Article Abstract Full Text PDF Download References References 1 Trousseau A. Phlegmasia Alba Dolens. Clinique Médicale de l’Hçtel Dieu de Paris, 2nd edition. Vol 3. Paris: JB Baillère; 1865: 659-712. 2 Cliffton EE, Grossi CE. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. Cancer 1955; 8: 1146-1154. 3 Grossi CE, Agostino D, Cliffton EE. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinoma. Cancer Res 1960; 20: 605-608. 4 Agostino D, Grossi CE, Cliffton EE. Effect of heparin on circulating Walker carcinosarcoma 256 cells. J Natl Cancer Inst 1961; 5: 463-473. 5 Cliffton EE, Agostino D. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism. Cancer 1962; 15: 276-283. 6 Agostino D, Cliffton EE, Girolami A. Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer 1966; 19: 284-288. 7 Dolfini E, Azzarone B, Pedulla D. et al. Characterization of human fibroblasts from cancer patients: Loss of fibrin clot retractile activity after ‘invitro’ spontaneous transformation. Eur J Cancer 1976; 12: 823-825. 8 Donati MB, Dolfini E, Morasca L. et al. Fibrin clot retraction by a rat rhabdomyosarcoma cell line. Thromb Res 1976; 8: 707-711. 9 Curatolo L, Colucci M, Cambini AL. et al. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 1979; 40: 228-233. 10 Poggi A, Polentarutti N, Donati MB. et al. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res 1977; 37: 272-277. 11 Chmielewska J, Poggi A, Mussoni L. et al. Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice. Eur J Cancer 1980; 16: 1399-1407. 12 Mussoni L, Poggi A, de Gaetano G. et al. Effect of ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. Br J Cancer 1978; 37: 126-129. 13 Poggi A, Mussoni L, Kornblihtt L. et al. Warfarin enantiomers, anticoagulation, and experimental tumor metastasis. Lancet 1978; 1: 163-164. 14 Chmielewska J, Poggi A, Janik P. et al. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. Eur J Cancer 1980; 16: 919-923. 15 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137. 16 Colucci M, Delaini F, De Bellis Vitti G. et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983; 32: 1689-1691. 17 Lorenzet R, Bottazzi B, Locati D. et al. Failure of warfar in to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. Eur J Cancer Clin Oncol 1985; 21: 263-265. 18 Donati MB, Gambacorti P, Casali B. et al. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 1986; 46: 6471-6474. 19 Grignani G, Falanga A, Pacchiarini L. et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 1988; 42: 554-557. 20 Falanga A, Alessio MG, Donati MB. et al. A new procoagulant in acute leukemia. Blood 1988; 71: 870-875. 21 Donati MB, Falanga A, Consonni R. et al. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemost 1990; 64: 11-16. 22 Falanga A, Iacoviello L, Evangelista V. et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86: 1072-1081. 23 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-5567. 24 Roncaglioni MC, D’Alessandro AP, Casali B. et al. Gamma-glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. Haemostasis 1986; 16: 295-299. 25 Lorenzet R, Peri G, Locati D. et al. Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-273. 26 Rambaldi A, Alessio G, Casali B. et al. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol 1986; 136: 3848-3855. 27 Donati MB, Davidson JD, Garattini S. Malignancy and the Hemostatic System. Raven Press; N.Y.: 1981 28 Levine MN, Gent M, Hirsh J. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407. 29 Levine M, Hirsh J, Gent M. et al. Double-blind randomised trial of a very-low-dose warfar in for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889. 30 Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 2003; 3: 421-422. 31 Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001; 106: 18-24. 32 Prandoni P, Lensing AW, Buller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133. 33 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410. 34 Lee AYY. Thrombosis and cancer: The role of screening for occult cancer and recognizing the underlying biological mechanisms. In: Hematology. 2006. Am Soc Hemat, Education Program Book; Bajus JL. Ed. p 438-443. 35 Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. Thromb Haemost 1989; 61: 526-528. 36 Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: Second report. Thromb Haemost 1993; 70: 357-360. 37 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2(Second International Study of Infarct Survival). Collaborative Group. Lancet 1988; 2: 349-360. 38 GISSI-2:a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardialin farction. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio. Lancet 1990; 336: 65-71. 39 Donati MB, Poggi A. Malignancy and haemostasis. Br J Haematol 1980; 44: 173-182. 40 Poggi A, Donati MB, Garattini S. Fibrin and cancer cell growth: Problems in the evaluation of experimental models. In: Malignancy and the hemostatic system. Raven Press; New York: 1981. pp. 89-101. 41 Bani MR, Falanga A, Alessio MG. et al. Blood coagulation changes in nude mice bearing human colon carcinomas. Int J Cancer 1992; 50: 75-79. 42 Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2004; 2: 1263-1265. 43 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153. 44 Altinbas M, Coskun HS, Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-1271. 45 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the framing advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948. 46 Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135. 47 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129. 48 Maugeri N, de Gaetano G, Barbanti M. et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparins. Haematologica 2005; 90: 815-821. 49 Maugeri N, Di Fabio G, Barbanti M. et al. Parnaparin, a low molecular weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007; 97: 965-973. 50 Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI?. Thromb Haemost 2002; 87: 928-929. 51 Donati MB, Lorenzet R. Coagulation factors and tumor cell biology: the role of tissue factor. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 22-25. 52 Donati MB, Falanga A, Lorenzet R. Cancer and thrombosis: a two way interaction. In: Thrombosis. Fundamental and clinical aspects. Leuven University Press; 2003. pp. 417-31.
